Semaphoring mAb: a New Guide in RIT in Inhibiting the Proliferation of Human Skin Carcinoma |
Liu, Yuan
(Department of Dermatovenereology, Tianjin Medical University General Hospital)
Ma, Jing-Yue (Department of Dermatovenereology, Tianjin Medical University General Hospital) Luo, Su-Ju (Department of Dermatovenereology, Tianjin Medical University General Hospital) Sun, Chen-Wei (Department of Dermatovenereology, Tianjin Medical University General Hospital) Shao, Li-Li (Department of Dermatovenereology, Tianjin Medical University General Hospital) Liu, Quan-Zhong (Department of Dermatovenereology, Tianjin Medical University General Hospital) |
1 | Abbasakoor F, Woodhams J, Farooqui N, et al (2013). Safe ablation of the anal mucosa and perianal skin in rats using photodynamic therapy-a promising approach for treating anal intraepithelial Neoplasia. Photodiagnosis Photodyn Ther, 10, 566-74. DOI |
2 | Al-Ejeh F BM (2011). Combined Modality Therapy: Relevance for Targeted Radionuclide Therapy., Philadelphia: Lippincott, Williams & Wilkinson. |
3 | Al-Ejeh F, Kumar R, Wiegmans A, et al (2010). Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene, 29, 6085-98. DOI ScienceOn |
4 | Bartkova J, Horejsi Z, Koed K, et al (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 434, 864-70. DOI |
5 | Bouilhol G, Ayadi M, Rit S, et al (2013). Is abdominal compression useful in lung stereotactic body radiation therapy? A 4DCT and dosimetric lobe-dependent study. Phys Med, 29, 333-40. DOI |
6 | Cagnoni G, Tamagnone L (2013). Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression. Oncogene, 33, 4795-802 |
7 | El-Domyati M, El-Ammawi TS, Medhat W, et al (2013). Expression of p53 protein after nonablative rejuvenation: the other side of the coin. Dermatol Surg, 39, 934-43. DOI |
8 | Frost SH, Back T, Chouin N, et al (2013). Comparison of 211At- PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm, 28, 108-14. DOI |
9 | Fujiwara K, Koyama K, Suga K, et al (2014). Combination radioimmunotherapy using 90Y labeled anti-ROBO1 IgG and chemotherapy improves survival rate of small cell lung cancer xenograft models. J Nucl Med Meeting Abstracts, 55, 1487-. |
10 | Grunberg J, Lindenblatt D, Dorrer H, et al (2014). Anti- L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model. Eur J Nucl Med Mol Imaging, 41, 1907-15. DOI |
11 | Guo Y, Parry JJ, Laforest R, et al (2013). The role of p53 in combination radioimmunotherapy with 64Cu-DOTAcetuximab and cisplatin in a mouse model of colorectal cancer. J Nucl Med, 54, 1621-9. DOI |
12 | Hohloch K, Lankeit HK, Zinzani PL, et al (2014). Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network. Eur J Nucl Med Mol Imaging, 41, 1585-92. DOI |
13 | Jandl T, Revskaya E, Jiang Z, et al (2013). Melanoma stem cells in experimental melanoma are killed by radioimmunotherapy. Nucl Med Biol, 40, 177-81. DOI |
14 | Kohno M, Ohara K, Horibe T, et al (2014). Inhibition of Neurite Outgrowth by a Neuropilin-1 Binding Peptide Derived from Semaphorin 3A. Interl J Peptide Res Therapeut, 20, 153-60. DOI |
15 | Kovtun YV, Audette CA, Ye Y, et al (2006). Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res, 66, 3214-21. DOI |
16 | Muratori C, Tamagnone L (2012). Semaphorin signals tweaking the tumor microenvironment. Adv Cancer Res, 114, 59-85. DOI |
17 | Sharkey RM, Goldenberg DM (2013). Antibody-targeted therapeutic radionuclides in the management of colorectal cancer. in 'Nuclear Medicine Therapy', Eds Springer, 207-37 |
18 | Nasarre P, Gemmill RM, Potiron VA, et al (2013). Neuropilin-2 Is upregulated in lung cancer cells during TGF-beta1-induced epithelial-mesenchymal transition. Cancer Res, 73, 7111-21. DOI |
19 | Nehil M, Paquette J, Tokuyasu T, et al (2013). High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A. Oncogene, 33, 5151-62 |
20 | Rehman M, Tamagnone L (2013). Semaphorins in cancer: biological mechanisms and therapeutic approaches. Semin Cell Dev Biol, 24, 179-89. DOI |
21 | Sommer G, Rossa C, Chi AC, et al (2011). Implication of RNAbinding protein La in proliferation, migration and invasion of lymph node-metastasized hypopharyngeal SCC cells. PLoS One, 6, 25402. DOI |
22 | Song H, Sgouros G (2011). Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv, 8, 26-44. DOI |
23 | Staudacher AH, Al-Ejeh F, Fraser CK, et al (2014). The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB (R). EJNMMI Res, 4, 2. DOI |
24 | Suzuki T, Hirakawa S, Shimauchi T, et al (2014). VEGF-A promotes IL-17A-producing gammadelta T cell accumulation in mouse skin and serves as a chemotactic factor for plasmacytoid dendritic cells. J Dermatol Sci, 74, 116-24. DOI |
25 | Tamagnone L (2012). Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell, 22, 145-52. DOI |
26 | Trotta R, Vignudelli T, Candini O, et al (2003). BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell, 3, 145-60. DOI |
![]() |